Leukemia patients with chronic phase Chronic Myelogenous Leukemia have increased cardiovascular events. Hyperhomocysteinemia and high doses of nilotinib favour these cardiovascular events. This study investigated the impact of these factors in a cohort of patients with Chronic Myelogenous Leukemia.

Disclosures: Gaëlle Fossard, Emilie Blond, Marie Balsat, Stéphane Morisset, Stephanie Giraudier, Martine Escoffre-Barbe, Hélène Labussière-Wallet, Maël Heiblig, Arthur Bert, Madeleine Etienne, Jocelyne Drai, Mohamad Sobh, Isabelle Redonnet-Vernhet, Jean-Christophe Lega, François-Xavier Mahon, Gabriel Etienne, and Franck Emmanuel Nicolini have no disclosures.

Contributions: GF has implemented some data, interpreted the data, seen some patients and wrote the paper. EB, JD, IR-V performed and supervised the biochemical assessments. MB, SG, ME-B, HL-W, MH, AB, JCL, FXM, GE and FE-N treated patients and collected clinical data. ME implemented the database. SM performed statistical analyses. MS performed editorial assistance. GE and FEN co-designed the study and set it up. FEN collected the data, supervised their implementation, and wrote the manuscript with GF. All contributors have reviewed this letter and given their agreement on the last version of this manuscript for publication.